Christine Duthoit

CEO -CSO RNAlead

Dr. Christine Duthoit is the CEO and CSO of RNAlead, a company dedicated to advancing and commercializing FlashRNA, a disruptive RNA delivery technology originally developed and patented at Flash Therapeutics. With over 16 years of experience at Flash Therapeutics prior to leading RNAlead, she has been instrumental in shaping and improving innovative RNA-based delivery platforms for diverse therapeutic applications.
Christine brings a strong scientific background, holding a Ph.D. and research experience in France and the United States, with a career-long passion for immunology and autoimmune diseases. She has been at the forefront of emerging immunotherapy strategies, recognizing their transformative potential not only in oncology but also across multiple therapeutic areas.
A committed leader and innovator, Christine combines deep scientific expertise with operational acumen to drive the development of groundbreaking RNA delivery technologies aimed at addressing some of today’s most pressing therapeutic challenges.

Seminars

Wednesday 28th January 2026
Expanding mRNA Therapeutic Horizons to Unlock New Targets Tissues & Indications Beyond Infectious Disease
2:00 pm
  • FlashRNA®: A disruptive RNA delivery technology for nextgeneration therapies
  • Discovering how mRNA is being applied to oncology, cardiovascular disease, and rare genetic conditions
  • Learning from companies breaking away from the vaccine narrative to pursue non-infectious targets
Christine Duthoit Speaker at 5th mRNA Based Therapeutics Summit Europe
View all Speakers
View Event Brochure